Trial Profile
Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms Endurance3
- 25 Mar 2019 Status changed from recruiting to completed.
- 11 Apr 2018 Planned End Date changed from 1 Dec 2017 to 11 Apr 2018.
- 30 Sep 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.